Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $35.04M
• Dividend Yield: N/A
• Average Volume (3M): 507.80K
• Price to Earnings (P/E): 2.1
• Beta (1Y): 0.23
• Revenue Growth: 51.27%
• EPS Growth: N/A
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 7,210,235
• 10 Day Avg. Volume: 261,759
• 30 Day Avg. Volume: 507,798
• PEG Ratio: 0.01
• Price to Book (P/B): -1.02
• Price to Sales (P/S): 0.77
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 2.44
• Enterprise Value/Revenue: 0.56
• Enterprise Value/Gross Profit: 0.69
• Enterprise Value/Ebitda: 2.80
• 1Y Price Target: $12.00
• Price Target Upside: -24.00% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $5.00 ▼(-68.33% Downside)

The score is primarily held down by weak financial performance (negative equity and ongoing cash burn) and very bearish technicals (price far below key moving averages with negative MACD). A highly negative corporate event (FDA CRL for EBVALLO) further increases risk, while the low P/E provides only partial support given the underlying uncertainty.

Positive Factors

High gross and improving operating margins

Sustained TTM gross margin above 80% and a shift to positive EBIT/EBITDA indicate durable product-level economics and improving operational efficiency. If commercialized, these margin dynamics support scalable profitability and a stronger operating leverage profile over the medium term.

Commercial partnership with Pierre Fabre

Having Pierre Fabre as a U.S. commercialization partner and transferring the BLA shifts regulatory and launch execution burdens to an established pharma partner. Their plan to seek a Type A meeting and revised milestone structure provides regulatory engagement and non-dilutive funding optionality, reducing solo execution risk.

Restructuring to reduce fixed costs

A deep restructuring with ~90% headcount cuts and lease downsizing materially reduces fixed operating expenses. This permanent cost-base reduction can extend runway, lower recurring burn, and allow management to focus capital on core programs, improving the firm's structural cash profile.

Negative Factors

Regulatory setback for lead asset

The CRL reverses prior FDA alignment and deems the single‑arm ALLELE trial inadequate, creating major regulatory uncertainty. This may require new evidence, additional trials, or prolonged negotiations, delaying approval, increasing development costs, and threatening the commercial outlook for the lead asset.

Negative stockholders' equity

Negative stockholders' equity signals deep balance sheet strain and limits borrowing capacity. For a capital‑intensive biotech, this reduces financial flexibility to fund trials or commercialization, likely necessitating dilutive financing or asset sales and increasing long‑term execution risk.

Ongoing cash burn and limited cash resources

Persistent negative operating and free cash flows, coupled with disclosures of year‑end cash around $8.5M, imply limited runway after restructuring. Continued cash burn will require milestone receipts, partner funding, or capital raises, raising dilution risk and stressing near‑term program continuity.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through collaborations, grants, and clinical trial partnerships. The company may receive milestone payments and royalties from strategic partnerships with larger pharmaceutical companies that help fund its research and development efforts. Significant partnerships can include co-development agreements or licensing deals, where Atara provides its technology and expertise in exchange for financial support and shared profits on future product sales. Additionally, the company may receive funding from government grants or public and private investors, particularly for its innovative therapies that address unmet medical needs.

Atara Biotherapeutics Financial Statement Overview

Summary

Financials are strained: revenue declined in the TTM period, cash flow remains negative (ongoing cash burn), and the balance sheet shows negative stockholders’ equity (financial instability). Positives include strong TTM gross margin and improvement to positive EBIT/EBITDA margins, but overall risk remains elevated.

Income Statement

Atara Biotherapeutics has shown inconsistent revenue growth with a notable decline in the TTM period. While the gross profit margin remains strong at over 81% in TTM, the net profit margin is low at 3.07%, indicating limited profitability. The company has improved from negative EBIT and EBITDA margins in previous years to positive margins in TTM, reflecting operational improvements.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is negative due to negative equity, which is concerning. Return on equity is also negative, reflecting poor returns for shareholders. The equity ratio is not calculable due to negative equity, highlighting potential financial distress.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth. However, both operating and free cash flows remain negative, indicating cash burn. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income to cash. The free cash flow to net income ratio is slightly above 1, showing some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.93M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	124.03M	107.93M	-313.00K	63.57M	-261.66M	-244.65M
EBITDA	30.50M	-75.75M	-266.00M	-222.26M	-331.12M	-300.72M
Net Income	23.40M	-85.40M	-276.13M	-228.30M	-340.14M	-306.62M
Balance Sheet
Total Assets	30.17M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	13.71M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	58.60M	43.83M	57.87M	71.70M	28.27M	15.03M
Total Liabilities	66.80M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-36.63M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-69.80M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-69.71M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	13.08M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	15.77M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Negative. The current price of 15.79 is above the 20-day moving average (MA) of 6.03, above the 50-day MA of 12.10, and above the 200-day MA of 11.24, indicating a bearish trend. The MACD of -2.25 indicates Negative momentum. The RSI at 26.58 is Positive, neither overbought nor oversold. The STOCH value of 19.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZNTL	53 Neutral	$184.24M	-1.06	-49.18%	―	-33.76%	17.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$202.71M	-0.97	―	―	-63.96%	-28.50%
TCRX	49 Neutral	$54.56M	-0.81	-76.44%	―	-10.03%	11.06%
MGNX	48 Neutral	$109.44M	-1.41	-81.13%	―	-9.70%	23.23%
ATRA	43 Neutral	$35.04M	2.06	―	―	51.27%	―

Atara Biotherapeutics Corporate Events

FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain

On January 12, 2026, Atara Biotherapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter for EBVALLO (tabelecleucel), rejecting its Biologics License Application as a monotherapy for EBV-positive post-transplant lymphoproliferative disease in adults and children, despite previously resolving manufacturing compliance issues and raising no new safety concerns. The FDA, reversing its earlier stance, now deems the single-arm ALLELE trial inadequate to demonstrate effectiveness for accelerated approval, prompting Atara’s U.S. commercialization partner Pierre Fabre to seek a Type A meeting as the companies work to salvage a path forward for the therapy, while Atara continues a deep restructuring marked by a roughly 90% headcount reduction in 2025, amended commercialization milestones, a significant lease downsizing, and year-end 2025 cash, cash equivalents and short-term investments of about $8.5 million, subject to audit.

The most recent analyst rating on (ATRA) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara revises tab-cel commercialization milestones with Pierre Fabre

On December 30, 2025, Atara Biotherapeutics amended its commercialization agreement with Pierre Fabre Medicament, reducing potential regulatory milestone payments tied to FDA approval of a BLA for tab-cel from $40 million to $31 million in exchange for the opportunity to earn an additional $15 million milestone based on achieving a specified commercial milestone. The revised structure adjusts the balance between regulatory and commercial incentives, potentially aligning Pierre Fabre’s financial commitments more closely with tab-cel’s market performance and affecting the timing and composition of future milestone revenues for Atara.

The most recent analyst rating on (ATRA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.